Generation Bio Co (GBIO)

Currency in USD
4.150
-0.130(-3.04%)
Closed·
After Hours
4.1500.000(0.00%)
·
GBIO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
GBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.1404.294
52 wk Range
3.00429.400
Key Statistics
Prev. Close
4.28
Open
4.28
Day's Range
4.14-4.294
52 wk Range
3.004-29.4
Volume
53.27K
Average Volume (3m)
123.42K
1-Year Change
-82.53%
Book Value / Share
10.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
70.000
Upside
+1,586.75%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Generation Bio Co News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Generation Bio Co Company Profile

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Generation Bio Co SWOT Analysis


T-Cell Revolution
Generation Bio pivots to T-cell driven autoimmune diseases, leveraging innovative ctLNP technology for siRNA delivery to potentially address undruggable targets
Moderna Synergy
Explore the $1.8 billion potential in milestone payments from Generation Bio's collaboration with Moderna, advancing stealth LNP platform for immune cell targeting
Financial Runway
With $185 million in cash, operations are funded into 2027, but market caution persists as the stock trades below cash position amid distant clinical timelines
Future Prospects
Delve into Generation Bio's ambitious development timeline, with lead target nomination by mid-2025 and Phase 1 trials expected between late 2026 and early 2027
Read full SWOT analysis

Compare GBIO to Peers and Sector

Metrics to compare
GBIO
Peers
Sector
Relationship
P/E Ratio
−0.4x−3.5x−0.5x
PEG Ratio
−0.01−0.010.00
Price/Book
0.4x1.1x2.6x
Price / LTM Sales
1.1x8.8x3.3x
Upside (Analyst Target)
-346.7%43.5%
Fair Value Upside
Unlock20.1%6.9%Unlock

Analyst Ratings

4 Buy
2 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 70.000
(+1,586.75% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-- / -0.2783
Revenue / Forecast
-- / 2.13M
EPS Revisions
Last 90 days

GBIO Income Statement

People Also Watch

17.96
SRPT
+10.46%
5.48
REPL
-0.36%
2.070
VOR
-0.96%
0.377
VYNE
+3.32%
2.240
UAVS
-3.03%

FAQ

What Stock Exchange Does Generation Bio Trade On?

Generation Bio is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Generation Bio?

The stock symbol for Generation Bio is "GBIO."

What Is the Generation Bio Market Cap?

As of today, Generation Bio market cap is 28.29M.

What Is Generation Bio's Earnings Per Share (TTM)?

The Generation Bio EPS (TTM) is -10.77.

When Is the Next Generation Bio Earnings Date?

Generation Bio will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is GBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Generation Bio Stock Split?

Generation Bio has split 1 times.

How Many Employees Does Generation Bio Have?

Generation Bio has 115 employees.

What is the current trading status of Generation Bio (GBIO)?

As of 07 Aug 2025, Generation Bio (GBIO) is trading at a price of 4.15, with a previous close of 4.28. The stock has fluctuated within a day range of 4.14 to 4.29, while its 52-week range spans from 3.00 to 29.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.